US 12,226,391 B2
Method of treating tumours
Victoria Anne Gordon, Yungaburra (AU); Paul Warren Reddell, Yungaburra (AU); Glen Mathew Boyle, Taringa (AU); Jason Kingsley Cullen, Thornside (AU); and Peter Gordon Parsons, St Lucia (AU)
Assigned to QBIOTICS PTY LTD, Queensland (AU)
Appl. No. 17/602,909
Filed by QBIOTICS PTY LTD, Taringa (AU)
PCT Filed Apr. 9, 2020, PCT No. PCT/AU2020/050360
§ 371(c)(1), (2) Date Oct. 11, 2021,
PCT Pub. No. WO2020/206504, PCT Pub. Date Oct. 15, 2020.
Claims priority of application No. 2019901280 (AU), filed on Apr. 12, 2019.
Prior Publication US 2022/0193023 A1, Jun. 23, 2022
Int. Cl. A61K 31/336 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/336 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61P 35/00 (2018.01)] 17 Claims
 
1. A method of stimulating tumour regression in at least one non-target tumour in a subject with multiple tumours, said method comprising administering to at least one target tumour a 6,7-epoxytiglienone compound or a pharmaceutically acceptable salt thereof as a monotherapy; wherein the at least one target tumour and the at least one non-target tumour are immunogenic tumours, and wherein administration is localised administration to the at least one target tumour; wherein the 6,7-epoxytiglienone compound is a compound of formula (I):

OG Complex Work Unit Chemistry
or a geometric isomer or stereoisomer or a pharmaceutically acceptable salt thereof;
wherein
R1 is hydrogen or C1-6alkyl;
R2 is —OR9;
R3 is —OH or —OR9;
R4 and R5 are independently selected from hydrogen and C1-6alkyl;
R6 is hydrogen or —R10;
R7 is hydroxy or —OR10;
R8 is hydrogen or C1-6alkyl;
R9 is —C1-20alkyl, —C2-20alkenyl, —C2-20alkynyl, —C(O)C1-20alkyl, —C(O)C2-20alkenyl, —C(O)C2-20alkynyl, —C(O)cycloalkyl, —C(O)C1-10alkylcycloalkyl; —C(O)C2-10alkenylcycloalkyl, —C(O)C2-10alkynylcycloalkyl, —C(O) aryl, —C(O)C1-10alkylaryl, —C(O)C2-10alkenylaryl, —C(O)C2-10alkynylaryl, —C(O)C1-10alkylC (O) R11, —C(O)C2-10alkenylC (O) R11, —C(O)C2-10alkynylC (O) R11, —C(O)C1-10alkylCH (OR11) (OR11), —C(O)C2-10alkenylCH (OR11) (OR11), —C(O)C2-10alkynylCH (OR11) (OR11), —C(O)C1-10alkylSR11, —C(O)C2-10alkenylSR11, —C(O)C2-10alkynylSR11, —C(O)C1-10alkylC(O)OR11, —C(O)C2-10alkenylC(O)OR11, —C(O)C2-10alkynylC(O)OR11, —C(O)C1-10alkylC(O)SR11, —C(O)C2-10alkenylC(O)SR11, —C(O)C2-10alkynylC(O)SR11,

OG Complex Work Unit Chemistry
R10 is —C1-6alkyl, —C2-6alkenyl, —C2-6alkynyl, —C(O)C1-6alkyl, —C(O)C2-6alkenyl, —C(O)C2-6alkynyl, —C(O) aryl, —C(O)C1-6alkylaryl, —C(O)C2-6alkenylaryl, —C(O)C2-6alkynylaryl; and
R11 is hydrogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, cycloalkyl or aryl;
wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted.